3-HO-PCP
3-Hydroxyphencyclidine is a dissociative of the arylcyclohexylamine class related to phencyclidine that has been sold online as a designer drug.Pharmacology
3-HO-PCP acts as a high-affinity uncompetitive antagonist of the NMDA receptor via the dizocilpine site. It has much higher affinity than PCP for this site. The drug also has high affinity for the μ-opioid receptor , the κ-opioid receptor , and the sigma σ1 receptor, whereas it has only low affinity for the δ-opioid receptor. The high affinity of 3-HO-PCP for opioid receptors is unique among arylcyclohexylamines and is in contrast to PCP, which has only very low affinity for the MOR and the other opioid receptors.
Although it was hypothesized that 3-HO-PCP might be a metabolite of PCP in humans, there is no evidence that this is the case.Chemistry
3-HO-PCP is an arylcyclohexylamine. Close analogues of 3-HO-PCP include PCP, 3-MeO-PCP, 4-MeO-PCP, 3-MeO-PCMo, and somewhat more distantly ketamine, methoxyketamine, 3-MeO-PCE, methoxetamine and 4--4-cyclohexanone.Society and culture
On October 18, 2012 the Advisory Council on the Misuse of Drugs in the United Kingdom released a report about methoxetamine, saying that the "harms of methoxetamine are commensurate with Class B of the Misuse of Drugs Act ", despite the fact that the act does not classify drugs based on harm. The report went on to suggest that all analogues of MXE should also become class B drugs and suggested a catch-all clause covering both existing and unresearched arylcyclohexamines, including 3-HO-PCP.
3-HO-PCP is banned in Sweden and Switzerland.
